Brought to you by 
BMS, Nektar build off of 2016 trial collaboration, sign official immuno-oncology deal; Deal ends after poor data analyses
22 Apr 2022
Executive Summary
Stemming from a September 2016 clinical trial collaboration testing the combination of Bristol-Myers Squibb Co.'s Opdivo (nivolumab) and Nektar Therapeutics' NKTR214 (bempegaldesleukin), the companies have now signed an agreement that lays out an official deal with cost and profit splits, as well as commercialization rights.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Trial Collaborations
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS, Nektar build off of 2016 trial collaboration, sign official immuno-oncology deal; Deal ends after poor data analyses
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice